For brain cancer patients exploring complementary or repurposed therapies, it is important to understand what the research actually shows—and what it does not.
Below is an evidence-based overview of fenbendazole and brain cancer.
- You are here:
- Home »
- Blog »
- brain cancer »
- Fenbendazole and Brain Cancer
Fenbendazole and Brain Cancer
Fenbendazole and Brain Cancer- Can a veterinary anti-parasite drug help fight brain tumors?
Interest in fenbendazole and brain cancer has grown rapidly in recent years. Fenbendazole is a benzimidazole anti-parasitic medication widely used in veterinary medicine to treat worms in animals. Recently, some cancer patients and researchers have explored whether this inexpensive drug might have anticancer effects, particularly against difficult cancers such as glioblastoma, the most aggressive form of brain cancer.
But what does the science actually say?
Below is a review of what researchers currently know about fenbendazole and related drugs in brain cancer, including laboratory findings, clinical research, and the limitations of the evidence.
I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths beyond conventional, FDA-approved therapies and taken great risks in an effort to manage my blood cancer. I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.
The post below is PeopleBeatingCancer’s effort to weigh in on the fenben and brain cancer debate. Please scroll down the page, post a question or a comment if you have any questions.
If you’d like to learn more about repurposed drugs and cancer treatment, click now.
Thank you,
David Emerson
What Is Fenbendazole?
Fenbendazole is an anthelmintic drug used to treat parasitic infections in animals such as dogs, cattle, goats, and horses. It works by binding to tubulin, a structural protein that forms microtubules within cells. When microtubules are disrupted, cells cannot divide properly and eventually die.
https://en.wikipedia.org/wiki/Fenbendazole
Because rapid cell division is a hallmark of cancer, researchers have investigated whether drugs that disrupt microtubules could potentially affect tumor growth.
However, it’s important to note that fenbendazole has not been approved for human use by the FDA, and clinical evidence for its effectiveness in cancer is extremely limited.
https://www.cancer.org/cancer/latest-news/what-to-know-about-fenbendazole.html
How Fenbendazole Could Treat Cancer (and Why It Won’t)
Why Researchers Are Studying Fenbendazole for Brain Cancer
Brain cancers such as glioblastoma (GBM) are among the most difficult cancers to treat. Standard therapy typically includes:
- Surgery
- Radiation therapy
- Chemotherapy (often temozolomide)
Despite aggressive treatment, the median survival for glioblastoma remains about 15–20 months, which is why researchers are actively investigating repurposed drugs.
Benzimidazole drugs such as fenbendazole, mebendazole, and albendazole have attracted attention because they may:
- Disrupt cancer cell microtubules
- Block tumor glucose metabolism
- Trigger cancer cell death (apoptosis)
- Interfere with tumor cell division
Laboratory studies show that fenbendazole can disrupt microtubule dynamics and alter cancer-related cellular pathways.
https://www.nature.com/articles/s41598-018-30158-6
Evidence for Benzimidazole Drugs in Brain Cancer
Most research on brain tumors has focused on mebendazole, a closely related drug in the same family as fenbendazole.
Laboratory and animal studies
In one widely cited study, researchers tested mebendazole in mouse models of glioblastoma.
Key findings:
- The drug disrupted microtubule formation in glioma cells
- Tumor growth slowed significantly
- Survival increased up to 63% in mouse models
Study:
https://pmc.ncbi.nlm.nih.gov/articles/PMC3158014/
Because benzimidazole drugs share a similar mechanism of action, scientists believe fenbendazole may exert similar effects, although direct evidence remains limited.
Ability to cross the blood-brain barrier
One major challenge in brain cancer treatment is that many drugs cannot penetrate the blood-brain barrier (BBB).
Mebendazole appears promising because it can penetrate the BBB and inhibit glioma progression by affecting pathways involved in cell proliferation and invasion.
https://www.mdpi.com/1422-0067/24/2/1334
This property is one reason researchers continue to investigate benzimidazole drugs for brain tumors.
Clinical trials in brain cancer
Researchers have already conducted early clinical trials evaluating mebendazole combined with standard therapy for high-grade glioma.
Example trial:
https://clinicaltrials.gov/study/NCT01729260
Early results suggest:
- The drug was generally well-tolerated
- It could potentially be combined with chemotherapy such as temozolomide
However, the trials were small and not designed to prove effectiveness, so larger studies are needed.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7817892/
Evidence Specifically for Fenbendazole
Evidence specifically for fenbendazole in brain cancer remains limited and mostly preclinical.
Laboratory research suggests that fenbendazole may:
- Disrupt tumor microtubules
- Reduce glucose uptake in cancer cells
- Activate tumor-suppressor pathways such as p53
- Induce apoptosis in rapidly dividing tumor cells
Study:
https://www.nature.com/articles/s41598-018-30158-6
However, other studies have found no clear antitumor benefit in certain models, highlighting the need for more research.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3580766/
Safety and Evidence Limitations
Despite growing interest, several important cautions remain:
1. Fenbendazole is not approved for humans
The drug is intended for animals, and its safety and efficacy for human cancer patients are not established.
https://www.cancer.org/cancer/latest-news/what-to-know-about-fenbendazole.html
2. Evidence is mostly laboratory-based
Most positive findings come from:
- cell culture experiments
- animal studies
Human clinical trials remain extremely limited.
3. Anecdotal reports are not proof
Some patients online claim tumor regression while taking fenbendazole. However, these individuals were often receiving other cancer therapies simultaneously, making it impossible to determine what caused the outcome.
Integrative Therapies That May Help Brain Cancer Patients
While research on fenbendazole is still evolving, several evidence-based complementary strategies may help support brain cancer patients:
Nutrition
- Anti-inflammatory diets
- ketogenic or metabolic therapy approaches under medical supervision
Exercise
Regular moderate exercise may help improve survival and quality of life in many cancer populations.
Sleep optimization
Circadian rhythm regulation may improve immune function.
Evidence-based supplements are often studied in brain tumors
- Curcumin
- Omega-3 fatty acids
- Melatonin
- Medicinal mushrooms (e.g., turkey tail)
These should always be discussed with a physician before use.
Bottom Line
Research into fenbendazole and brain cancer is still in its early stages.
Key takeaways:
- Fenbendazole belongs to a class of drugs (benzimidazoles) that can disrupt cancer cell microtubules.
- Laboratory studies suggest potential anticancer effects.
- Related drugs like mebendazole have shown promising results in glioblastoma models and early clinical trials.
- However, clinical evidence in humans remains limited, and fenbendazole is not approved for human cancer treatment.
More research is needed before doctors can determine whether fenbendazole or related drugs might play a meaningful role in treating brain cancer.
To Learn More About Repurposed Drugs for Cancer-
- Fenbendazole and Cancer: What the Research Really Shows”
- Mebendazole and Cancer: Anti-Tumor Mechanisms and Studies”
- Repurposed Drugs in Cancer Therapy: What the Science Shows”
- Metformin and Cancer: Why a Diabetes Drug Is Being Studied for Tumors
- Repurposed Drugs in Cancer Therapy: What the Science Shows
- Repurposed Drugs + Chemotherapy: Integrative Treatment
Research References
- Bai RY et al. Antiparasitic mebendazole shows survival benefit in preclinical glioblastoma models.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3158014/ - Gallia GL et al. Mebendazole with temozolomide in high-grade glioma.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7817892/ - Dogra N et al. Fenbendazole exhibits antitumor activity through microtubule disruption.
https://www.nature.com/articles/s41598-018-30158-6 - Duan Q et al. Fenbendazole as a potential anticancer drug.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3580766/ - Meco D et al. Emerging perspectives on mebendazole in cancer therapy.
https://www.mdpi.com/1422-0067/24/2/1334 - American Cancer Society – What to know about fenbendazole.
https://www.cancer.org/cancer/latest-news/what-to-know-about-fenbendazole.html - Fenbendazole and Brain Cancer Fenbendazole and Brain Cancer Fenbendazole and Brain Cancer